Ovarian function suppression is beneficial in some premenopausal women with early breast cancer

Key Points

• Premenopausal women with HR-positive early breast cancer benefit from exemestane plus OFS versus tamoxifen with or without OFS.
• Results of SOFT and TEXT support the addition of OFS to exemestane or tamoxifen in premenopausal women whose risk of recurrence warrants (neo)adjuvant chemotherapy.
• Women with low-risk early breast cancer derive minimal benefit from the addition of OFS.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/29lcFsG
via IFTTT